# FRAmework-01 (NCT07213804)

> A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07213804
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis
- Interventions: Sofetabart Mipitecan; Paclitaxel; Topotecan; Gemcitabine; Pegylated liposomal doxorubicin (PLD); MIRV; Bevacizumab; Carboplatin
- Enrollment: 1630
- Primary outcome: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
- Primary outcome: PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded, Independent, Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- Podcasts: 2
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=framework-01-nct07213804